Discriminating Feature: Positive Predictive Value in Low-Prevalence Settings
Key Point
In low-prevalence populations, specificity (not sensitivity) is the dominant determinant of PPV. The second test with 95% specificity will have substantially higher PPV than the first test with 85% specificity, despite lower sensitivity.
Calculation of PPV
Using the formula: PPV=TP+FPTP=(Sensitivity×Prevalence)+(1−Specificity)×(1−Prevalence)Sensitivity×Prevalence
Test 1 (Sens 95%, Spec 85%):
PPV1=(0.95×0.01)+(0.15×0.99)0.95×0.01=0.0095+0.14850.0095=0.1580.0095≈6
Test 2 (Sens 80%, Spec 95%):
PPV2=(0.80×0.01)+(0.05×0.99)0.80×0.01=0.008+0.04950.008=0.05750.008≈14
Clinical Interpretation
| Feature | Test 1 (95% Sen, 85% Spec) | Test 2 (80% Sen, 95% Spec) |
|---|
| Sensitivity | 95% (better for ruling out) | 80% |
| Specificity | 85% (poor for ruling in) | 95% (excellent for ruling in) |
| PPV @ 1% prevalence | ~6% | ~14% |
| NPV @ 1% prevalence | ~99.9% | ~99.8% |
| Clinical role | Screening (SnNout) | Confirmation (SpPin) |
High-YieldNEET PG
In low-prevalence settings, a positive test from the high-specificity test is 2× more likely to be a true positive than from the high-sensitivity test. This is the best discriminator between the two tests' clinical utility.
Clinical Pearl
Test 1 is superior for ruling out disease (high sensitivity, high NPV). Test 2 is superior for ruling in disease (high specificity, high PPV). The question asks which feature distinguishes them — PPV is the critical discriminator in this population.
